Skip to main content
Erschienen in: Clinical and Experimental Nephrology 6/2014

01.12.2014 | Commentary

A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients

verfasst von: Masaki Ohya, Takashi Shigematsu

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Excerpt

In recent years, there have been an increasing number of reports about the association between hyperuricemia and other diseases such as hypertension, hyperlipidemia, arteriosclerosis, cardiovascular disease and chronic kidney disease [13]. Allopurinol has long been regarded as a first-line drug for the treatment of hyperuricemia, but side effects such as renal dysfunction, hepatic dysfunction, Stevens-Johnson syndrome, and hypersensitivity vasculitis have been reported [46]. New urate-lowing agent had been expected during long time like 30 years or more. …
Literatur
1.
Zurück zum Zitat Kansui Y, Ohtsubo T, Goto K, et al. Association of serum uric acid with blood pressure in Japanese men: cross-sectional study in work-site group. Circ J. 2011;75:2827–32.PubMedCrossRef Kansui Y, Ohtsubo T, Goto K, et al. Association of serum uric acid with blood pressure in Japanese men: cross-sectional study in work-site group. Circ J. 2011;75:2827–32.PubMedCrossRef
2.
Zurück zum Zitat Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.PubMedCrossRef Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.PubMedCrossRef
3.
Zurück zum Zitat Toda A, Ishizaka Y, Tani M, et al. Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. Nephron Clin Pract. 2014;15(126):33–8.CrossRef Toda A, Ishizaka Y, Tani M, et al. Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. Nephron Clin Pract. 2014;15(126):33–8.CrossRef
4.
Zurück zum Zitat Becker MA, Schumachar HR, Wortmann RL, et al. Febuxostat compared allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.PubMedCrossRef Becker MA, Schumachar HR, Wortmann RL, et al. Febuxostat compared allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.PubMedCrossRef
5.
Zurück zum Zitat Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopirinol is common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.PubMedCrossRef Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopirinol is common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32.PubMedCrossRef
6.
Zurück zum Zitat Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523–6.PubMedCrossRef Fagugli RM, Gentile G, Ferrara G, et al. Acute renal and hepatic failure associated with allopurinol treatment. Clin Nephrol. 2008;70:523–6.PubMedCrossRef
7.
Zurück zum Zitat Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008;108:69–78.CrossRef Sánchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008;108:69–78.CrossRef
8.
Zurück zum Zitat Sánchez-Lozada LG, Tapia E, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23:1179–85.PubMedCrossRef Sánchez-Lozada LG, Tapia E, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23:1179–85.PubMedCrossRef
9.
Zurück zum Zitat Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549–56.PubMedCrossRef Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549–56.PubMedCrossRef
10.
Zurück zum Zitat Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38(3):258–61.PubMedCrossRef Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J Clin Pharm Ther. 2013;38(3):258–61.PubMedCrossRef
Metadaten
Titel
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients
verfasst von
Masaki Ohya
Takashi Shigematsu
Publikationsdatum
01.12.2014
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 6/2014
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-0989-7

Weitere Artikel der Ausgabe 6/2014

Clinical and Experimental Nephrology 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.